Vaginal vs. Laparoscopic Hysterectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02059954
Recruitment Status : Completed
First Posted : February 11, 2014
Last Update Posted : April 17, 2018
Austrian Urogynecology Working Group (AUWG)
Information provided by (Responsible Party):
Medical University of Graz

Brief Summary:

Hysterectomy for benign indication is one of the most common surgical procedures in women. Numerous reviews and guidelines recommend the vaginal approach for benign hysterectomy, but the proportion of laparoscopic (and robotic) hysterectomies is increasing.

This study will compare a range of clinical and subjective outcomes of vaginal vs. total laparoscopic hysterectomy. Outcomes include operating time, postoperative recovery, return to work as well as cosmesis, quality of life and sexual health.

Condition or disease Intervention/treatment Phase
Uterine Fibroids Uterine Leiomyoma Abnormal Uterine Bleeding, Unspecified Procedure: Hysterectomy Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Vaginal Hysterectomy Versus Total Laparoscopic Hysterectomy for Benign Indications: A Randomized Controlled Trial
Actual Study Start Date : January 2014
Actual Primary Completion Date : August 2016
Actual Study Completion Date : September 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hysterectomy

Arm Intervention/treatment
Active Comparator: Vaginal hysterectomy
Vaginal hysterectomy
Procedure: Hysterectomy
Active Comparator: Total laparoscopic hysterectomy
Laparoscopic hysterectomy
Procedure: Hysterectomy

Primary Outcome Measures :
  1. Operating time (min.) [ Time Frame: Surgery ]
    Operating time (min.)

Secondary Outcome Measures :
  1. Complications [ Time Frame: 6 weeks ]
    Intraoperative and postoperative complications

  2. Anesthesia time (min.) [ Time Frame: surgery ]
  3. Quality of life [ Time Frame: 12 months ]
  4. Sexual health [ Time Frame: 12 months ]
  5. Return to work [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • benign indication for vaginal hysterectomy (e.g., abnormal uterine bleeding, fibroids, atypical endometrial hyperplasia)
  • clinical exam indicates vaginal hysterectomy is feasible
  • no major concomitant surgery
  • able to complete questionnaires in German

Exclusion Criteria:

  • uterine malignancy
  • major concomitant surgery (e.g., for incontinence or prolapse)
  • clinical exam indicating vaginal hysterectomy not feasible
  • contraindication for surgery or laparoscopy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02059954

Krankenhaus der Barmherzigen Brüder, Abteilung Gynäkologie
Graz, Austria, 8020
Medical University of Graz/Dept. OB/GYN
Graz, Austria, 8036
LKH Leoben/Abteilung Gynäkologie
Leoben, Austria, 8700
Sponsors and Collaborators
Medical University of Graz
Austrian Urogynecology Working Group (AUWG)
Study Chair: Karl F Tamussino, MD Medical University of Graz
Principal Investigator: Rene W Laky, MD Medical University of Graz

Responsible Party: Medical University of Graz Identifier: NCT02059954     History of Changes
Other Study ID Numbers: 26-122 ex 13/14
MUG 26-122 ex 13/14 ( Other Identifier: MUGraz )
First Posted: February 11, 2014    Key Record Dates
Last Update Posted: April 17, 2018
Last Verified: April 2018

Keywords provided by Medical University of Graz:

Additional relevant MeSH terms:
Uterine Hemorrhage
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases
Uterine Diseases
Genital Diseases, Female
Pathologic Processes